
This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
This white paper from Ascendia Pharma details four factors to consider when selecting a CDMO for your next drug development project.






